Literature DB >> 33653773

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer.

Xinan Wang1,2, Biagio Ricciuti3, Tom Nguyen3, Xihao Li1,4, Michael S Rabin3, Mark M Awad3, Xihong Lin4, Bruce E Johnson3, David C Christiani5,6.   

Abstract

Lung carcinogenesis is a complex and stepwise process involving accumulation of genetic mutations in signaling and oncogenic pathways via interactions with environmental factors and host susceptibility. Tobacco exposure is the leading cause of lung cancer, but its relationship to clinically relevant mutations and the composite tumor mutation burden (TMB) has not been fully elucidated. In this study, we investigated the dose-response relationship in a retrospective observational study of 931 patients treated for advanced-stage non-small cell lung cancer (NSCLC) between April 2013 and February 2020 at the Dana Farber Cancer Institute and Brigham and Women's Hospital. Doubling smoking pack-years was associated with increased KRASG12C and less frequent EGFRdel19 and EGFRL858R mutations, whereas doubling smoking-free months was associated with more frequent EGFRL858R . In advanced lung adenocarcinoma, doubling smoking pack-years was associated with an increase in TMB, whereas doubling smoking-free months was associated with a decrease in TMB, after controlling for age, gender, and stage. There is a significant dose-response association of smoking history with genetic alterations in cancer-related pathways and TMB in advanced lung adenocarcinoma. SIGNIFICANCE: This study clarifies the relationship between smoking history and clinically relevant mutations in non-small cell lung cancer, revealing the potential of smoking history as a surrogate for tumor mutation burden. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33653773      PMCID: PMC8137661          DOI: 10.1158/0008-5472.CAN-20-3991

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  27 in total

1.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient.

Authors:  William Lee; Zhaoshi Jiang; Jinfeng Liu; Peter M Haverty; Yinghui Guan; Jeremy Stinson; Peng Yue; Yan Zhang; Krishna P Pant; Deepali Bhatt; Connie Ha; Stephanie Johnson; Michael I Kennemer; Sankar Mohan; Igor Nazarenko; Colin Watanabe; Andrew B Sparks; David S Shames; Robert Gentleman; Frederic J de Sauvage; Howard Stern; Ajay Pandita; Dennis G Ballinger; Radoje Drmanac; Zora Modrusan; Somasekar Seshagiri; Zemin Zhang
Journal:  Nature       Date:  2010-05-27       Impact factor: 49.962

Review 2.  The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.

Authors:  Lynette M Sholl; Fred R Hirsch; David Hwang; Johan Botling; Fernando Lopez-Rios; Lukas Bubendorf; Mari Mino-Kenudson; Anja C Roden; Mary Beth Beasley; Alain Borczuk; Elisabeth Brambilla; Gang Chen; Teh-Ying Chou; Jin-Haeng Chung; Wendy A Cooper; Sanja Dacic; Sylvie Lantuejoul; Deepali Jain; Dongmei Lin; Yuko Minami; Andre Moreira; Andrew G Nicholson; Masayuki Noguchi; Mauro Papotti; Giuseppe Pelosi; Claudia Poleri; Natasha Rekhtman; Ming-Sound Tsao; Erik Thunnissen; William Travis; Yasushi Yatabe; Akihiko Yoshida; Jillian B Daigneault; Ahmet Zehir; Solange Peters; Ignacio I Wistuba; Keith M Kerr; John W Longshore
Journal:  J Thorac Oncol       Date:  2020-06-06       Impact factor: 15.609

Review 3.  Evolving concepts in lung carcinogenesis.

Authors:  Brigitte N Gomperts; Avrum Spira; Pierre P Massion; Tonya C Walser; Ignacio I Wistuba; John D Minna; Steven M Dubinett
Journal:  Semin Respir Crit Care Med       Date:  2011-04-15       Impact factor: 3.119

4.  Modeling lung cancer risk in case-control studies using a new dose metric of smoking.

Authors:  Sally W Thurston; Geoffrey Liu; David P Miller; David C Christiani
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-10       Impact factor: 4.254

5.  Institutional implementation of clinical tumor profiling on an unselected cancer population.

Authors:  Lynette M Sholl; Khanh Do; Priyanka Shivdasani; Ethan Cerami; Adrian M Dubuc; Frank C Kuo; Elizabeth P Garcia; Yonghui Jia; Phani Davineni; Ryan P Abo; Trevor J Pugh; Paul van Hummelen; Aaron R Thorner; Matthew Ducar; Alice H Berger; Mizuki Nishino; Katherine A Janeway; Alanna Church; Marian Harris; Lauren L Ritterhouse; Joshua D Campbell; Vanesa Rojas-Rudilla; Azra H Ligon; Shakti Ramkissoon; James M Cleary; Ursula Matulonis; Geoffrey R Oxnard; Richard Chao; Vanessa Tassell; James Christensen; William C Hahn; Philip W Kantoff; David J Kwiatkowski; Bruce E Johnson; Matthew Meyerson; Levi A Garraway; Geoffrey I Shapiro; Barrett J Rollins; Neal I Lindeman; Laura E MacConaill
Journal:  JCI Insight       Date:  2016-11-17

Review 6.  Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.

Authors:  Léa Berland; Simon Heeke; Olivier Humbert; Adam Macocco; Elodie Long-Mira; Sandra Lassalle; Virginie Lespinet-Fabre; Salomé Lalvée; Olivier Bordone; Charlotte Cohen; Sylvie Leroy; Véronique Hofman; Paul Hofman; Marius Ilié
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

7.  Tumor Origins Through Genomic Profiles.

Authors:  Edison T Liu; Susan M Mockus
Journal:  JAMA Oncol       Date:  2020-01-01       Impact factor: 31.777

8.  Implementing TMB measurement in clinical practice: considerations on assay requirements.

Authors:  Reinhard Büttner; John W Longshore; Fernando López-Ríos; Sabine Merkelbach-Bruse; Nicola Normanno; Etienne Rouleau; Frédérique Penault-Llorca
Journal:  ESMO Open       Date:  2019-01-24

9.  Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

Authors:  Natalie I Vokes; David Liu; Biagio Ricciuti; Elizabeth Jimenez-Aguilar; Hira Rizvi; Felix Dietlein; Meng Xiao He; Claire A Margolis; Haitham A Elmarakeby; Jeffrey Girshman; Anika Adeni; Francisco Sanchez-Vega; Nikolaus Schultz; Suzanne Dahlberg; Ahmet Zehir; Pasi A Jänne; Mizuki Nishino; Renato Umeton; Lynette M Sholl; Eliezer M Van Allen; Matthew D Hellmann; Mark M Awad
Journal:  JCO Precis Oncol       Date:  2019-11-12

Review 10.  Next generation sequencing-based gene panel tests for the management of solid tumors.

Authors:  Masayuki Nagahashi; Yoshifumi Shimada; Hiroshi Ichikawa; Hitoshi Kameyama; Kazuaki Takabe; Shujiro Okuda; Toshifumi Wakai
Journal:  Cancer Sci       Date:  2018-11-27       Impact factor: 6.716

View more
  19 in total

1.  Response to Hopkins, Kichenadasse, Logan, et al.

Authors:  Xinan Wang; Biagio Ricciuti; Joao V Alessi; Tom Nguyen; Mark M Awad; Xihong Lin; Bruce E Johnson; David C Christiani
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 11.816

2.  Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer.

Authors:  Ke Xu; Haitang Yang; Wenyan Ma; Liwen Fan; Beibei Sun; Zhexin Wang; Mohammad Faisal Al-Hurani; Ralph A Schmid; Feng Yao
Journal:  J Thorac Dis       Date:  2021-12       Impact factor: 2.895

3.  Implementation of smoking signature as an improved biomarker predicting the response to immunotherapy.

Authors:  Haitang Yang; Wenyan Ma; Feng Yao
Journal:  Transl Lung Cancer Res       Date:  2022-01

4.  Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.

Authors:  Li-Yue Sun; Wen-Jian Cen; Wen-Ting Tang; Ya-Kang Long; Xin-Hua Yang; Xiao-Meng Ji; Jiao-Jiao Yang; Ren-Jing Zhang; Fang Wang; Jian-Yong Shao; Zi-Ming Du
Journal:  Cancer Med       Date:  2021-09-01       Impact factor: 4.452

5.  Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients.

Authors:  Haitang Yang; Wenyan Ma; Beibei Sun; Liwen Fan; Ke Xu; Sean R R Hall; Mohammad Faisal Al-Hurani; Ralph A Schmid; Ren-Wang Peng; Toyoaki Hida; Zhexin Wang; Feng Yao
Journal:  Transl Lung Cancer Res       Date:  2021-09

6.  The Frequency of DNA Mismatch Repair Deficiency Is Very Low in Surgically Resected Lung Carcinoma.

Authors:  Naoki Yanagawa; Noriyuki Yamada; Ryo Sugimoto; Mitsumasa Osakabe; Noriyuki Uesugi; Satoshi Shiono; Makoto Endoh; Shin-Ya Ogata; Hajime Saito; Makoto Maemondo; Tamotsu Sugai
Journal:  Front Oncol       Date:  2021-10-06       Impact factor: 6.244

7.  Smoking signature as a biomarker for immunotherapy.

Authors:  Mengqian Li; Lin-Yong Zhao
Journal:  Transl Lung Cancer Res       Date:  2022-01

8.  Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.

Authors:  Xinan Wang; Biagio Ricciuti; Joao V Alessi; Tom Nguyen; Mark M Awad; Xihong Lin; Bruce E Johnson; David C Christiani
Journal:  J Natl Cancer Inst       Date:  2021-06-11       Impact factor: 11.816

9.  UGT1A1 Gene Polymorphism Contributes as a Risk Factor for Lung Cancer: A Pilot Study with Patients from the Amazon.

Authors:  Esdras E B Pereira; Luciana P C Leitão; Roberta B Andrade; Antônio A C Modesto; Bruno M Fernandes; Rommel M R Burbano; Paulo P Assumpção; Marianne R Fernandes; João F Guerreiro; Sidney E B Dos Santos; Ney P C Dos Santos
Journal:  Genes (Basel)       Date:  2022-03-11       Impact factor: 4.096

10.  Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature.

Authors:  Sara Baglivo; Martina Mandarano; Guido Bellezza; Vincenzo Minotti; Angelo Bonaiti; Matthias J Fischer; Ilaria Birocchi; Fausto Roila; Niccolò Metelli; Vienna Ludovini; Giulio Metro
Journal:  Oncol Ther       Date:  2022-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.